Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001621 · ClinicalTrials.gov registry record
Evaluation and Treatment of Patients With Lung Disease Not Participating in Research
A clinical trial of Pulmonary Disease, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 280
- Enrollment target
- 1
- Study location
NCT00001621: Completed study of Pulmonary Disease, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00001621 is a study of Pulmonary Disease that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 280 participants, below the 610-participant average among 19 other Pulmonary Disease trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001621, a study of Pulmonary Disease, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 280 participants
- Enrollment target
- 1
- Study location
Study Summary
This study was developed in order for the professional-staff at the Pulmonary-Critical Care Medical Branch (PCCMB) of the National Heart, Lung, and Blood Institute to maintain their skills and increase their understanding of lung diseases. The study will permit PCCMB staff members to evaluate and treat patients with lung disease who do not meet the criteria for other research studies.
Primary Outcome
The purpose of this protocol is to permit PB staff to evaluate and treat patients with pulmonary disease who do not meet the criteria for existing research protocols.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 1997-02-12 |
| Est. Completion | 2020-09-25 |
What the finished NCT00001621 record still lists
NCT00001621 is an observational study that tracks outcomes without assigning an intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, below the 610-participant average among 19 other Pulmonary Disease trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Pulmonary Disease appearing as the primary indexed condition, and to 0 interventions.
NCT00001621 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00001621 about?
NCT00001621 is a clinical study titled "Evaluation and Treatment of Patients With Lung Disease Not Participating in Research". This study was developed in order for the professional-staff at the Pulmonary-Critical Care Medical Branch (PCCMB) of the National Heart, Lung, and Blood Institute to maintain their skills and increase their understanding of lung diseases. The study will permit PCCMB staff members to evaluate and t...
What is the current status of trial NCT00001621?
This trial is currently completed. The enrollment target is 280 participants. The study started on 1997-02-12. Estimated completion is 2020-09-25.
What conditions does trial NCT00001621 study?
This clinical trial studies the following conditions: Pulmonary Disease.
Who is sponsoring clinical trial NCT00001621?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001621 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001621's enrollment target sits among peer trials
280 8th of 19 higher than 12 of 19 other Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exhaled Breath: A Novel Technique for Rapid Diagnosis of Respiratory Diseases and Infections
RECRUITING
-
Quantitative Pulmonary Imaging Registry & Biorepository
RECRUITING
-
Merck IIT: RRP Pembro and Lenvatinib
RECRUITING · Early Phase 1
-
Study of Lung Proteins in Patients With Pneumonia
RECRUITING
-
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
RECRUITING
-
Risk Underlying Rural Areas Longitudinal Cohort Study (RURAL) Heart and Lung Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI